Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-557-8 | CAS number: 354-33-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: (1a) GLP Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- GLP compliance:
- yes
Test material
- Reference substance name:
- Pentafluoroethane
- EC Number:
- 206-557-8
- EC Name:
- Pentafluoroethane
- Cas Number:
- 354-33-6
- Molecular formula:
- C2HF5
- IUPAC Name:
- 1,1,1,2,2-pentafluoroethane
- Details on test material:
- - Name of test material (as cited in study report): HFC-125
- Substance type: fluorinated alkane
- Physical state: gas
- Analytical purity: > 99.5%
- Impurities (identity and concentrations): not reported
- Composition of test material, percentage of components: Pure substance
- Isomers composition: n/a
- Purity test date: not reported
- Lots/batches No.: BR070, BR163, BR016
- Expiration date of the lot/batch: not reported
- Stability under test conditions: stable
- Storage condition of test material: stored in pressure gas cylinders at room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan
- Age at study initiation:
- Weight at study initiation:
- Fasting period before study:
- Housing:
- Diet (e.g. ad libitum):
- Water (e.g. ad libitum):
- Acclimation period:
ENVIRONMENTAL CONDITIONS
- Temperature (°C):
- Humidity (%):
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light):
IN-LIFE DATES: From: To:
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- HFC-125 vapours were generated by metering the gaseous HFC-125 form a cylinder into stainless tubing through the flow meter. The vapour was
diluted with filtered air to the desired concentrations.
Chamber concentrations were obtained by varying the gas flow rate in the chambers.
FIltered air alone was metered in an identical way in the control chamber. The atmospheric concentrations were monitored at intervals of 15 minutes
by GC analysis. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- GC analysis:
chamber atmosphere was sampled with an automatic system (0.2 ml/sample) and analysed with a Shimadzu GC-8AIF GC.
Technical details: Detector: flame ionization detector; Column: 3m x 3mm I.D. stainless steel packed with 20% DC-200 liquid phase on a 60/80 mesh chromosorb W solid phase; Program: isotherm 60°C.
A standard curve was obtained by measuring the signal of several concentrations of pure HFC-125. - Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- 6 hrs/day, 5 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
5000, 15000 and 50000 ppm
Basis:
nominal conc.
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: Based on the low toxicity observed in the acute study
- Rationale for animal assignment: After the quarantine period, the animals were divided in groups of 10 rats/sex by means of a computerised
"adequate stratification method". The fluctuation of body weight means was kept within 20% in each group.
- Post-exposure recovery period in satellite groups: 2 additional groups of 10 rats/sex were exposed to 0 and 50,000 ppm for 4 weeks and
subsequently kept for a 2-week recovery period.
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: before exposure period. day 1, 2 and 5 on the 1st week of exposure. Weekly as from the second week of exposure
and throughout the exposure and the recovery period till to the day before termination.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, weekly
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at termination
- Anaesthetic used for blood collection: Yes
- Animals fasted: Yes 12-24 h before the withdrawal
- How many animals: all
- Parameters checked in table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at termination
- Animals fasted: Yes, 12-24 h before the withdrawal
- How many animals: All
- Parameters checked in table 2 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: 5th day of the 4th and 6th weeks
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters examined: see table 3 - Sacrifice and pathology:
- ORGAN WEIGHT: Yes, see table 4
GROSS PATHOLOGY: At the end of the study all animals were subjected to gross pathology examination
HISTOPATHOLOGY: Yes, see table 5 - Other examinations:
- PEROXISOME PROLIFERATION:
- the livers of all animals exposed to 0 and 50,000 ppm were checked for peroxisome proliferation. - Statistics:
- Dunnett's test was used for determining the significant difference of test values of bodyweight, food consumption, blood chemistry, haematology
and organ weight. The X2 test was used for determining the significant differences of urinary test values. T-test was used for the statistical analysis of the recovery groups parameters and for determining the significant differences
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No mortality was observed. Skin ulcer was observed for one female of high-dose group during treatment and recovery period. No other clinical
signs were observed
BODY WEIGHT AND WEIGHT GAIN
There were no differences in body weight among the treated groups and the control group.
FOOD CONSUMPTION
There were no differences in food consumption among the treated groups and the control group.
FOOD EFFICIENCY
--
WATER CONSUMPTION
--
OPHTHALMOSCOPIC EXAMINATION
--
HAEMATOLOGY AND CLINICAL CHEMISTRY (Tab 6)
A statistically higher mean corpuscolar haemoglobin concentration (MCHC) was measured in the males of high dose group, compared to control.
however no dose dependence was observed. No haematological changes were observed in treated animals in comparison to controls at the end of
the recovery period.
Males of high-dose group had a statistically higher concentration of plasma phospholipids compared to control.
Males exposed to 5000 and 15000, but not 50000 ppm had a lower albumine content.
Males of the exposed recovery group had a statistically higher plasma albumine and total protein values compared to control recovery group.
URINALYSIS
No treatment related findings were observed in urinalysis
NEUROBEHAVIOUR
--
ORGAN WEIGHTS
No treatment related findings were observed.
GROSS PATHOLOGY
No dose-related changes were observed in treated animals at the end of exposure and recovery period.
HISTOPATHOLOGY
No compound related changes were found at the end of exposure and recovery periods.
OTHER FINDINGS: Peroxisome proliferation
A higher activity was measured in liver samples of male high-dose group in comparison to control. However the female high-dose group had a lower activity compared to control.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- >= 50 000 ppm
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- urinalysis
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 6.Findings in haematology and blood chemistry in males (**=p<0.01; *=p<0.05)
Main group |
MCHC(g/dl) |
Albumin(g/dl) |
Phopsholipid(mg/dl) |
control |
34.0+/-0.3 |
3.8+/-0.1 |
98+/-14 |
5000 ppm |
34.8+/-0.3 |
3.7+/-0.1* |
98+/-10 |
15000 ppm |
34.5+/-0.3 |
3.7+/-0.1* |
103+/-12 |
50000 ppm |
34.5 +/-0.4** |
3.8 +/-0.1 |
113+/-14* |
RECOVERY |
|
|
|
control |
34.8+/-1.3 |
6.1 +/-0.2 |
115 +/-14 |
50000 ppm |
34.2+/-0.4 |
6.3+/-0.2* |
114+/-22 |
Applicant's summary and conclusion
- Conclusions:
- 50,000 ppm was considered the NOAEL of the study.
- Executive summary:
Groups of 10 male and 10 female Sprague Dawley rats were exposed to 0, 5000, 15,000 and 50,000 ppm (0, 24,544, 73,632 and 245,440 mg/m3) HFC-125 for 28 days (6 hours/day, 5 days/week). Two additional groups were exposed to 0 and 50,000 ppm HFC-125 and were allowed to recover for two weeks after the exposure period.
No mortality was observed in this study. There were no treatment-related clinical signs of toxicity and differences in body weight and food consumption among the treated and the control groups, neither after the exposure nor after the recovery period. Some effects were observed in the haematology and blood chemistry analysis. In particular, a very slight, not dose-related increase in mean corpuscular haemoglobin concentration was measured in the males of all the treatment groups at the end of the exposure period; only the increase at the highest dose was statistically significant in comparison with the controls. Males exposed to 5,000 and 15,000, but not to 50,000 ppm, showed a slightly lower serum albumin content. A slight increase in serum phospholipids concentration was measured in the males of high-dosed group, at the end of exposure period. No haematological findings were observed in the recovery groups. Neither macroscopic nor microscopic changes were observed during gross pathology and histological examinations, respectively. Study of peroxisomal proliferation gave equivocal results, since a slightly higher activity of peroxisomal beta-oxidation was measured in the males of the high-dosed group in comparison to control; while a lower activity was measured in the females of the same group. 50,000 ppm was considered the NOAEC of this study in view of the low toxicological relevance of most of the observed effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.